Search

Your search keyword '"Yuzuka Kanno"' showing total 2 results
Start Over Author "Yuzuka Kanno" Language english
2 results on '"Yuzuka Kanno"'

1. Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers

Author

Yuzuka Kanno, Chang-Yu Chen, Hsin-Lun Lee, Jeng-Fong Chiou, and Yin-Ju Chen

Subjects
head and neck cancer, chemotherapy resistance, chemotherapy, immunotherapy, combination therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Chemotherapy resistance is a huge barrier for head and neck cancer (HNC) patients and therefore requires close attention to understand its underlay mechanisms for effective strategies. In this review, we first summarize the molecular mechanisms of chemotherapy resistance that occur during the treatment with cisplatin, 5-fluorouracil, and docetaxel/paclitaxel, including DNA/RNA damage repair, drug efflux, apoptosis inhibition, and epidermal growth factor receptor/focal adhesion kinase/nuclear factor-κB activation. Next, we describe the potential approaches to combining conventional therapies with previous cancer treatments such as immunotherapy, which may improve the treatment outcomes and prolong the survival of HNC patients. Overall, by parsing the reported molecular mechanisms of chemotherapy resistance within HNC patient’s tumors, we can improve the prediction of chemotherapeutic responsiveness, and reveal new therapeutic targets for the future.

Published
2021
Full Text
View/download PDF

2. A Combined Systemic Strategy for Overcoming Cisplatin Resistance in Head and Neck Cancer: From Target Identification to Drug Discovery

Author

Ann-Joy Cheng, Long Sheng Lu, Chang Yu Chen, Yuzuka Kanno, Meng Yu Lai, Lai Lei Ting, Jeng Fong Chiou, Hsin Lun Lee, Guo Rung You, and Yin Ju Chen

Subjects
0301 basic medicine, Cancer Research, SPC25, lcsh:RC254-282, Article, Transcriptome, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, medicine, Gene silencing, Viability assay, celastrol, Cisplatin, mitotic division, biology, Chemistry, Cancer, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030104 developmental biology, Oncology, Cell culture, Celastrol, 030220 oncology & carcinogenesis, Cancer research, biology.protein, head and neck cancer, cisplatin resistance, transcriptome, medicine.drug, RHEB
Abstract

Cisplatin is the first-line chemotherapy agent for head and neck cancer (HNC), but its therapeutic effects are hampered by its resistance. In this study, we employed systemic strategies to overcome cisplatin resistance (CR) in HNC. CR cells derived from isogenic HNC cell lines were generated. The CR related hub genes, functional mechanisms, and the sensitizing candidates were globally investigated by transcriptomic and bioinformatic analyses. Clinically, the prognostic significance was assessed by the Kaplan&ndash, Meier method. Cellular and molecular techniques, including cell viability assay, tumorsphere formation assay, RT-qPCR, and immunoblot, were used. Results showed that these CR cells possessed highly invasive and stem-like properties. A total of 647 molecules was identified, and the mitotic division exhibited a novel functional mechanism significantly related to CR. A panel of signature molecules, MSRB3, RHEB, ULBP1, and spindle pole body component 25 (SPC25), was found to correlate with poor prognosis in HNC patients. SPC25 was further shown as a prominent molecule, which markedly suppressed cancer stemness and attenuated CR after silencing. Celastrol, a nature extract compound, was demonstrated to effectively inhibit SPC25 expression and reverse CR phenotype. In conclusion, the development of SPC25 inhibitors, such as the application of celastrol, maybe a novel strategy to sensitize cisplatin for the treatment of refractory HNC.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results